cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Moleculin Biotech Inc
22 own
26 watching
Current Price
$0
$0
(0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
35.78M
52-Week High
52-Week High
2.05
52-Week Low
52-Week Low
0.817
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization35.78M
icon52-Week High2.05
icon52-Week Low0.817
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Moleculin Biotech Inc do?
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company s flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Read More
How much money does Moleculin Biotech Inc make?
News & Events about Moleculin Biotech Inc.
Accesswire
28days ago
- Live video webcast presentations with participating companies -FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ('JTC'), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event...
Ticker Report
1month ago
StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report released on Thursday morning. The brokerage issued a sell rating on the stock. Separately, Oppenheimer dropped their price target on shares of Moleculin Biotech from $14.00 to $5.00 in a...
PR Newswire
1month ago
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C...
PR Newswire
2 months ago
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme PR Newswire HOUSTON, Dec. 7, 2022 HOUSTON, Dec. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc...
Ticker Report
2 months ago
StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX Get Rating) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock. A number of other research firms also recently weighed in on MBRX. Oppenheimer decreased their ...
Frequently Asked Questions
Frequently Asked Questions
What is Moleculin Biotech Inc share price today?
plus_minus_icon
Can Indians buy Moleculin Biotech Inc shares?
plus_minus_icon
How can I buy Moleculin Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Moleculin Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Moleculin Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Moleculin Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Moleculin Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Moleculin Biotech Inc?
plus_minus_icon
What percentage is Moleculin Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Moleculin Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(0.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00